T he incidences of obesity and type 2 diabetes mellitus are approaching epidemic levels in both developing and industrialized countries. Patients with type 2 diabetes mellitus are at increased risk of heart failure, and there is evidence for the distinct clinical entity of diabetic cardiomyopathy 1 independent of traditional cardiovascular risk factors. The spectrum of disease ranges from subclinical left ventricular (LV) diastolic and systolic dysfunction, 2 to overt systolic dysfunction in advanced disease. Its causes may be attributed to microvascular disease, metabolic disturbances, myocardial fibrosis and steatosis, cardiac autonomic dysfunction, and insulin resistance. 1
1. HbA1c <7.0%.
2.
Resting supine blood pressure ≤130/80 mm Hg. 3 . Total cholesterol <4.0 mmol/L and low-density lipoprotein cholesterol <2.0 mmol/L, triglycerides <1.0 mmol/L.
Patients were advised to following a diet of low glycemic index and to reducing excessive carbohydrate and fat intake. Patients with overweight or obesity were recommended a healthy balanced diet but aimed at reduced energy intake. Patients who struggled with their diet were referred for individual dietitian consultation. Treatment was maintained and monitored for 12 months, at which time all patients underwent repeat echocardiogram.
Echocardiography Protocols
All patients underwent rest echocardiography followed by symptomlimited exercise echocardiography at baseline.
Two-Dimensional and Doppler Echocardiography
Transthoracic echocardiography (TTE) were performed with Vivid E9, GE Medical Systems. All standard echo and Doppler parameters of LV systolic and diastolic function including pulse wave tissue Doppler were measured.
Strain Imaging
Global mean peak longitudinal strain (GLS) of the LV was obtained with 2-dimensional (2D) speckle-tracking analyses in apical 4-chamber, 2-chamber, and long-axis views using highest possible frame rates. Analyses were performed by experienced observers blinded to the clinical history and metabolic profiles. The GLS was calculated from the 3 GLS curves of the 3 apical views (Figure 1 ). All Doppler and 2D speckle-tracking echocardiographic measurements were taken as averages of 3 representative cycles. Our inter-and intraobserver variability in measurement of LV GLS have been reported. 12 
Calibrated Integrated Backscatter
The cIB curves were extracted in the parasternal long-axis view, using standard software (Echopac; GE Vingmed). Measurements were obtained by placing a 8×8 mm region of interest in the subendocardial basal anteroseptum, posterior wall, and pericardium at the peak of the R wave on the ECG in the parasternal long-axis view. cIB was obtained by subtracting average pericardial backscatter intensity from average myocardial backscatter intensity of the anteroseptum or posterior wall.
Inter-and Intraobserver Variability Analysis
LV GLS measurements were repeated in 10 randomly selected patients by the same observer (M.L.) on the same echocardiographic images, and by a second observer (D.L.) to determine intra-and interobserver variability, respectively.
Statistical Analysis
Continuous variables were presented as mean±1 SD, but for metabolic measures median ( To reduce the impact of extreme outliers in some metabolic variables, we reported proportions of those variables whose follow-up values were less than the baseline values (lower) and compared the change using the sign test. Pearson correlation coefficient was used to assess inter-and intraobserver variability, correlations between baseline body mass index (BMI) and baseline GLS, and between changes in Medical Research Council dyspnea grade with changes in GLS, and changes in HbA1c. Linear regression was performed to identify the relationship between improvement in GLS and e′ with changes in HbA1c. Multiple linear regression was used to identify independent predictors of GLS and e′ velocity at follow-up and changes in these outcomes (Δparameters) from their respective baseline values. Clinical, biochemical, and echocardiographic parameters were chosen on a priori grounds based on published studies and biological plausibility. Parameters with P<0.2 on univariable analysis were entered into the final multivariable model as explanatory variables. Independent contribution was then assessed, and there was no evidence of significant multicollinearity. The anthropometric and metabolic values at 12-month followup were used for predicting GLS and e′ on follow-up. Changes between baseline and 12-month follow-up (Δ-parameters) for the continuous variables were used to predict ΔGLS and Δe′. Baseline GLS and e′ measures were also included as covariates in the respective models. Case elimination was used for missing data. No significant differences in demographic, anthropometric, or metabolic variables were observed between the intervention participants (n=105), and those who declined were excluded from the study or lost to follow-up (n=46; 57% men; age, 49 years). Nonparticipants had similar echo parameters (mean GLS−14.5%; mean septal e′ 6 cm/s), except for a lower LVEF (57±13% versus 62±10%; P=0.016). Statistical analyses were performed using STATA version 12 (STATA Corporation, College Station, TX) and R v3.2.2.
Results
Of the 151 patients screened and considered eligible for entry into the study, 33 declined to participate, as they were not able to commit to the follow-up schedule. Of the 118 patients recruited in the study, 3 patients had abnormal stress echocardiograms and were excluded. Ten patients (8.7%) were lost to follow-up. Therefore, 105 patients completed follow-up.
Baseline Clinical and Echocardiographic Characteristics
The 105 patients (69 men) had a mean age of 54±10 years, and mean duration of diabetes mellitus of 10.4±7.1 years. Their baseline and 12-month clinical, anthropometric, and metabolic characteristics are presented in Table 1 . Fewer than 5% of patient records were missing information. Patients had poorly controlled diabetes mellitus: 6 patients had HbA1c <8.0%, 27 had HbA1c between 8.0% and 9.0%, 25 patients had HbA1c between 9.0% to 10.0%, and 47 patients had HbA1c >10.0%. Seventy-two (69%) patients had hypertension, 86 (82%) had hypercholesterolemia, 58 (55%) had microalbuminuria, and up to 27% had other microvascular complications. The majority of patients (76%) experienced exertional dyspnea.
Baseline echocardiographic parameters are presented in Table 2 . Patients had normal LV mass indexed for body surface area and ejection fraction. LV diastolic function was impaired: septal e′ velocities were low, and LV filling pressures were elevated. Mean GLS was −14.9%, indicating impaired systolic function despite an ejection fraction of 62%. GLS was significantly correlated with BMI (r=0.33; P=0.001). However, there was no significant correlation between GLS or septal e′ velocities with baseline HbA1c. Septal E/e′ ratio was not correlated with HbA1c or BMI.
Metabolic Control
The changes in medications and metabolic control over the 12-month follow-up period are shown in Table 1 . When compared with baseline, more patients were on insulin, biguanides, and β-blockers at follow-up. HbA1c improved significantly from 10.3% to 8.3% (P<0.001). There was reduction in total cholesterol, with no significant changes in low-density lipoprotein, high-density lipoprotein, triglycerides, systolic blood pressure, or BMI.
The extent of reduction in HbA1c in our patients is shown in Figure 2 . None of the patients developed a new cardiovascular event during the study. One patient had an episode of significant hypoglycemia requiring presentation to the emergency department during the study. Table 3 shows the baseline characteristics of the patients divided according to whether they improved their HbA1c by ≥1%. Patients whose HbA1c decreased by ≥1% on follow-up had higher HbA1c and worse LV function at baseline.
Change in Cardiac Function and Its Determinants

LV Systolic Function
Both LV ejection fraction and GLS improved ( Table 2) . There was a progressively greater improvement in GLS as the patients achieved a lower final HbA1c with patients with a final HbA1c of <7.0% having the largest improvement ( Figure 2A ).
Patients who lowered their HbA1c by ≥1.0% had a significantly higher relative improvement in GLS than those who did not (30.2% versus 2.8%; P<0.001; Figure 3 ). There was a greater improvement in GLS in patients who had greater reduction in HbA1c ( Figure 2B ). The 15 patients whose HbA1c increased experienced a decline in GLS.
There was a linear relationship between change in HbA1c and change in GLS, such that reductions in HbA1c were associated with relative improvements in GLS, represented by the following equation:
During the 12-month study period, only 42 subjects (40%) achieved some degree of weight loss. There was no significant difference in the improvement in GLS comparing these 42 subjects with those whose BMI remained unchanged or increased (23.3% versus 19.9%; P=0.52). However, in univariable analysis, BMI reduction and improvement in GLS were weakly associated (r=0.20; P=0.05). Associations between change in low-density lipoprotein-cholesterol and systolic or diastolic blood pressure and change in GLS were not significant.
Change in HbA1c, change in BMI, treatment with metformin, and baseline GLS were independent predictors of change (Table 4) .
Improvements in Medical Research Council dyspnea grade were correlated with improvements in GLS (r=0.32; P<0.001) and improvements in HbA1c (r=0.27; P=0.005).
LV Diastolic Function
Relative improvements in septal e′ were 24±45% on follow-up. Patients were divided into 2 groups by whether their HbA1c had lowered by ≥1.0%. Patients whose HbA1c had lowered by ≥1.0% had significantly higher relative improvement in e′ compared than those who did not (32% versus 8%; P=0.003). However, patient groups with final HbA1c of ≤7.0% and >7.0% did not differ in relative improvement in e′ (22% versus 28%; P=0.40). There was a linear relationship between reduction in HbA1c and relative improvement in e′:
Relative ∆Septal e' = 6.228 − 8.971 × ∆HbA1c (R 2 =0.232, p<0.001)
There was no significant difference in relative improvement in e′ in the 42 patients whose BMI decreased when compared with the rest whose BMI remained the same or increased (18% versus 28%; P=0.23).
Only baseline e′ velocities and change in HbA1c were independent predictors of change in septal e′ velocities from baseline values at follow-up. Baseline e′ velocities, HbA1c and BMI at follow-up were independent predictors of septal e′ velocities at follow-up (Table 5 ).
Calibrated Integrated Backscatter
Changes in HbA1c were not significantly associated with changes in either the anteroseptal or the posterior wall cIB (r=0.15, P=0.13; r=0.03, P=0.79).
Inter-and Intraobserver Variability
The intraobserver mean differences for LV GLS were -0.19±0.36% (r=0.994). The interobserver mean differences were -0.33±1.02% (r=0.94).
Discussion
Consistent with other published studies, 3, 4, [13] [14] [15] our study demonstrated that patients with type 2 diabetes mellitus have impaired LV systolic and diastolic function despite a normal LV ejection fraction. Our study also showed that better glycemic control over a 12-month period resulted in improvements in LV systolic and diastolic function. Those who had the largest decrease in HbA1c had the greatest improvement in LV systolic and diastolic function, whereas patients with the lowest HbA1c at follow-up had the largest improvement in LV systolic function. Furthermore, improvements in systolic function and HbA1c were associated with improved filling parameters and exercise tolerance as reflected by reduction in E/e′ ratio and Medical Research Council dyspnea score.
LV Systolic and Diastolic Function in Diabetes Mellitus
Patients with type 2 diabetes mellitus may develop subclinical LV dysfunction. The Strong Heart Study demonstrated impaired LV systolic function in type 2 diabetes mellitus with Doppler echocardiography. 16 Fang et al 17 found a high prevalence of subclinical LV systolic and diastolic dysfunction in patients with type 2 diabetes mellitus without ischemia or LV hypertrophy manifest as impaired systolic and diastolic myocardial velocities. When asymptomatic patients with type 2 diabetes mellitus were compared with age-and BMI-matched controls, patients with diabetes mellitus had impaired longitudinal, but preserved circumferential and radial systolic as well as diastolic function. 4 The underlying pathophysiologic mechanisms of diabetic cardiomyopathy are multifactorial, but hyperglycemia is considered a central driver triggering maladaptive responses leading to myocardial dysfunction. 18 However, the evidence to date on the relationship between glycemic control and cardiac function has been contradictory. Some studies have shown that poor glycemic control was associated with abnormal LV relaxation, elevated LV filling pressures, and lower systolic strain. 13, 19, 20 Patients who had poorly controlled diabetes mellitus in the Strong Heart Study were found to have abnormal LV relaxation. 20 In 120 patients with type 2 diabetes mellitus after exclusion of ischemia and LV hypertrophy, peak systolic strain was independently associated with HbA1c levels, whereas septal e′ velocities were more related to age and hypertension but not related to glycemic control. 13 However, other studies have demonstrated no significant association between glycemic control and cardiac function. [21] [22] [23] [24] [25] The lack of correlation between systolic and diastolic function with HbA1c at baseline in our patients may have been because of the selection criteria: our patients were selected into the study as they all had poor glycemic control.
Impact of Metabolic Control on LV Function
We attempted to improve the patients' metabolic profiles. The main impact, however, of our intervention was in the significant improvement of glycemic control, with lowering of the patients' HbA1c from 10.3% to 8.3%.
The few studies that previously examined the impact of glycemic lowering on cardiac function using current standards of clinical care and evaluation gave inconsistent results. The study by von Bibra et al 26 showed that intensive metabolic control with insulin therapy resulted in improvements in diastolic but not in systolic function, whereas studies by others failed to demonstrate improvements in either diastolic or systolic function, using tissue Doppler and ejection fraction measures, despite better glycemic control. [27] [28] [29] Most of these studies examined intensified glycemic control over shorter periods of time than our study, and it is possible that these short periods of improved glycemic control were insufficient for detectable changes in cardiac function to occur.
Our study demonstrated that both the degree of improvement when compared with baseline and the final glycemic status determined the improvement in LV systolic function. Furthermore, patients who had worsened glycemic control experienced further deterioration of LV systolic function. This is consistent with longitudinal studies of asymptomatic patients with type 2 diabetes mellitus demonstrating progressive deterioration in LV strain despite LV ejection fraction remaining normal.
There were more patients on β-blockers at the end of the study, and it is possible that this may have an impact on LV function. However, only 10 patients were started on either metoprolol or atenolol during the study for hypertension, and β-blockade was not a predictor of improvement in either systolic or diastolic function in this study. Several other changes in metabolic and anthropometric parameters were found to be independent predictors of improvement in LV function at follow-up. A decrease in BMI was found to be beneficial to LV systolic function. Patients whose BMI decreased had similar relative improvements in e′ velocities when compared with those whose BMI did not decrease on follow-up. A much larger decrease in BMI, a greater number of patients who achieve weight loss, or a longer follow-up period may have been necessary to show any significant beneficial effects of a decrease in BMI on its own on e′ velocities. β-blocker and metformin therapy was associated with improvement in LV systolic function, and LV posterior wall cIB was associated with GLS at follow-up. Although these findings could only be hypothesis generating, they are consistent with other published studies and may shed some light on the underlying pathophysiologic mechanism of LV dysfunction in patients with diabetes mellitus. In a mice model of diabetes mellitus, metformin therapy helped preserve cardiac function 30 and such therapy in subjects with diabetes mellitus and heart failure was associated with lower morbidity and mortality. 31 Myocardial triglyceride content is found to be increased in diabetes mellitus and is associated with LV diastolic dysfunction 32 and caloric restriction in obese patients with type 2 diabetes mellitus led to a decreased myocardial triglyceride content and improved diastolic function. 33 That improvement in glycemic control improves cardiac function and dyspnea, and worsening control is associated with deterioration in cardiac function, underline the absolute importance of enhancing glycemic control in potentially reducing progression to heart failure and overt diabetic cardiomyopathy. The present study provides evidence for the first specific therapeutic intervention for diabetic heart disease. Although achieving current treatment targets is important, our study suggests that any glycemic improvement, no matter how high the initial HbA1c results in improved LV function. LV GLS and septal e′ velocities have proven advantages over LV ejection fraction and mitral E and A velocities as measures of LV systolic and diastolic function, respectively. Furthermore, LV GLS has incremental prognostic value over ejection fraction over a wide range of cardiovascular diseases. 34 Therefore, in our study, we were interested to identify predictors of the changes in LV function parameters and their absolute values on follow-up. Our study demonstrated significant improvement in LV GLS with improved glycemic control. Whether this improved GLS will translate into any clinical benefits cannot be answered with our data. However, given its demonstrated incremental prognostic value, 33 improved LV GLS may have a role to play in reducing the progression to clinical heart failure in diabetic cardiomyopathy. Furthermore, a recent long-term outcome study in asymptomatic patients with type 2 diabetes mellitus showed high prevalence of subclinical LV dysfunction despite normal LV ejection fraction. Over a median follow-up of 7.4 years, LV GLS was found to be an independent predictor of total mortality and hospitalization in additional to systolic blood pressure and HbA1c. 5
Limitations
This study was conducted as a single-arm interventional study, with each patient acting as their own control as it would have been unethical to have patients with poorly controlled diabetes mellitus in a control arm having no intervention. We instead sought to compare those who improved glycemic control with those who did not. Furthermore, the effects of improved glycemic control on LV function observed in this study are only preliminary and are not supported by hard clinical end points. Larger studies are needed to confirm the findings.
This study just fell short of achieving the lipid targets for our patients as a group. This was most likely because of the fact that most patients were already on a statin with or without ezetimibe, as well as antihypertensive agents on entry into the study. Those who were not on a statin tended to be those who declined or were unable to tolerate a statin. By the end of the follow-up period, patients had been up-titrated to the maximum tolerated statin/ezetimibe dose.
Although a large proportion of patients improved their glycemic control during the study, most did not achieve a target HbA1c of <7.0% at 12 months. The inability to achieve glycemic target highlights the difficulties and complexities in managing some patients with diabetes mellitus. Nevertheless, we think that more intensive input from a dietitian, exercise physiologist, and diabetes mellitus educator would have helped greater number of patients achieve their glycemic targets and thus strengthen the outcome of our intervention.
Conclusions
Patients with type 2 diabetes mellitus and poor metabolic control have impaired LV systolic and diastolic function. Tightening of glycemic control over a 12-month period led to improvements in LV systolic and diastolic function. This may have long-term prognostic implications. Estimates and P values from multivariable linear regression. HbA1c indicates glycated hemoglobin; and LV, left ventricular. *ΔSeptal e′ velocity was given by septal velocity at follow-up minus the septal e′ velocity at baseline.
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